ProQR Therapeutics (PRQR) Total Current Liabilities (2013 - 2025)

ProQR Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $37.8 million for Q4 2025.

• In Q4 2025, Total Current Liabilities fell 9.16% year-over-year to $37.8 million; the TTM figure through Dec 2025 stood at $37.8 million (down 9.16% YoY), while the FY2025 annual figure was $37.8 million, down 9.16% from the prior year.
• Total Current Liabilities came in at $37.8 million for Q4 2025 at ProQR Therapeutics, down from $41.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $41.6 million in Q4 2024 to a low of $12658.2 in Q1 2021.
• A 5-year average of $27.2 million and a median of $28.1 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 99.87% in 2021 and jumped 210168.06% in 2022, its largest moves.
• ProQR Therapeutics' Total Current Liabilities stood at $31.6 million in 2021, then tumbled by 32.17% to $21.4 million in 2022, then surged by 71.86% to $36.8 million in 2023, then advanced by 12.96% to $41.6 million in 2024, then declined by 9.16% to $37.8 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $37.8 million, $41.6 million, and $36.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison